No Data
No Data
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Not Many Are Piling Into Jaguar Health, Inc. (NASDAQ:JAGX) Stock Yet As It Plummets 39%
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome With Intestinal Failure (SBS-IF)
Jaguar Health Extends Collaboration With Streeterville to Develop P-300
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Unlock the Full List